HTDS - Hard to Treat Diseases (PINK)

[shockdragon]

OTTAWA, March 17 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) Collagenna Skin Care Products will commence shipments to Brazil shortly.

Collagenna Skin Products has received its first major order for shipments to its distribution partner Collagenna do Brasil.

Collagenna's CEO Michael Arnkvarn states: "As I have mentioned in the past, this has been an unusually long process in order to get past the bureaucratic maze to send products to probably one of the most protected markets in the world. But we have persisted and our main client has remained patient and committed to offering the Collagenna Product line to their customers. We will now be able to ship on a monthly basis and we expect the volume to double by this year's fourth quarter. The fact remains that the Purchase Order we have received is the single largest order in our history. This is the first of many more to come and we are committed to expanding our international and domestic markets."

Over 600 products have been ordered with a retail value of approximately $36,000. The order is expected to be expedited by the end of March 2010.

The company reminds our shareholders and followers to monitor PinkSheets.com Filing Section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send the company a direct message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company's competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumors, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the Exposing Stock Bashers website. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and other media that provide safe refuge to these individuals and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in the company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Hard to Treat Diseases (HTDS) Melem Secrets' Collagenna Skin Care To Commence Product Shipments to Brazil

[bdogsdad]

I hate that "don't be a victim crap. If they spent half the money on accountants that they spend on "end the bashing" websites, they would have audited financials by now and the price would probably be over a nickel. Whatever. I'm still not adding any more shares until I see SEC filings or audited financials.

[shockdragon]

BELGRADE, SERBIA, March 23 /PRNewswire-FirstCall/ - Slavica Biochem (Homepage | Slavica Biochem), registered subsidiary of Hard to Treat Diseases (Welcome to HTDS Medical), has released its RD (research and development) expenditures for 2009.

The List comprises of expenses connected with the purchase of laboratory equipment, travel and other miscellaneous expenses necessary for the operation, cooperation and coordination of Slavica BioChem's business and research. As HTDS does not subscribe to Pink Sheets filing service. The company followers may review this exhausting list of expenditures on the company IR web site 'Filings and News' section. See "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/

Slavica BioChem also continues its commitment to a development of its own division devoted to Regenerative medicine.

Regenerative Medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. This field holds the promise of regenerating damaged tissues and organs in the body by stimulating previously irreparable organs to heal themselves.

Scientific research is working to make treatments available for clinical use. Treatments include both in vivo and in vitro procedures. In vivo meaning studies and trials performed inside the living body in order to stimulate previously irreparable organs to heal themselves. In vitro treatments are applied to the body through implantation of a therapy studied inside the laboratory.

The company will advise the shareholders on all developments in timely manner.

The company reminds its shareholders and followers to our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Slavica BioChem (HTDS) Releases Its Bio Chem Expenditures 2009

[bdogsdad]

Ok, so what's the point?

[shockdragon]

OTTAWA, March 25 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) Further to the previously announced cosmetics merger (press release Feb 25, 2010) between Melem Secret's and Collagenna Skin Care Products, the company has decided to develop its neutraceutical business of supplements and natural health products under the Melem Secret brand.

Collagenna's CEO Michael Arnkvarn states: "We have been promoting a few supplements for optimal skin care but we have identified several other health products which we would like to bring to market. We feel that we need to create a brand independent of our skin care line. The Melem Secret brand will focus mainly on supplements and natural health products and Collagenna will continue its Skin Care brand."

New packaging is being developed along with a total revamp of the website Melem Secret to reflect this new direction. Melem Secret has retained the services of a professional internet marketer in order to jump start the marketing efforts of the new brand. The new brand launch is expected to start in about 15-30 days and it will feature the introduction of Melem Secret's new Baobab supplement. This product originates from Africa and has mainly highly attractive health benefits: high antioxidant value, high source of calcium, rich in iron, potassium, magnesium and Vitamin C.

Other products that are ready to be marketed by Melem Secret include Marine Collagen Capsules, Omega 3 gel capsules as well as the Skin Defense Complex Caps.

The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Hard to Treat Diseases (HTDS) Melem Secrets' Neutraceutical Products

[bdogsdad]

Got a little pop off that news but I don't believe it will stay up there long.. Still holding 1.35 mil shares..

[crammerfool]

I was on this before but decided to get off the train as it really did not seem to be going anywhere.

[bdogsdad]

Probably a good move, these guy's might get this moving one day but they have a lot of problems..

[biotechbob]

Are people playing HGSI as if it's a company with legitimate potential? This company strikes me as a pump and dump. Does HGSI have any upcoming FDA dates or clinical trials in the United States?

[bdogsdad]

I'm not in it at all. I would exercise caution.